Assuntos
Cardiologia , Doença da Artéria Coronariana , Dietoterapia/métodos , Hipertrigliceridemia , Política Nutricional , Comportamento de Redução do Risco , Cardiologia/métodos , Cardiologia/tendências , Fatores de Risco Cardiometabólico , Regras de Decisão Clínica , Consenso , Doença da Artéria Coronariana/prevenção & controle , Doença da Artéria Coronariana/terapia , Humanos , Inibidores de Hidroximetilglutaril-CoA Redutases/uso terapêutico , Hipertrigliceridemia/etiologia , Hipertrigliceridemia/metabolismo , Hipertrigliceridemia/psicologia , Hipertrigliceridemia/terapia , Administração dos Cuidados ao Paciente/normas , Medição de Risco/métodos , Estados UnidosRESUMO
Pancreatitis is a very rare adverse effect of quetiapine treatment, with only 5 cases of quetiapine-associated pancreatitis reported in the English literature to date. Herein, we report one patient who developed severe hypertriglyceridemia (>1000 mg/dL) after quetiapine administration, resulting in acute pancreatitis. An analysis of the underlying pathogenic mechanisms and a review of relevant literature are also presented. Clinicians should be aware of the potentially life-threatening metabolic disturbances and/or pancreatitis associated with quetiapine therapy.
Assuntos
Transtorno Bipolar/tratamento farmacológico , Transtorno Bipolar/psicologia , Dibenzotiazepinas/uso terapêutico , Hipertrigliceridemia/tratamento farmacológico , Hipertrigliceridemia/psicologia , Pancreatite/tratamento farmacológico , Pancreatite/psicologia , Doença Aguda , Humanos , Fumarato de QuetiapinaRESUMO
OBJECTIVE: Aging is associated with a loss of cognitive performance and an increasing occurrence of cardiovascular events. Moreover, cardiovascular risk factors are linked to cognitive impairment and dementia. Whereas individual components of metabolic syndrome (Met S) have been reported to be linked to cognitive decline and dementia, there are very few studies on Met S as a whole. The present study aims to assess the relationship between Met S and its components and cognitive functioning in a cohort of elderly non-demented community residents. DESIGN: Population-based cohort study (PROOF study). Cross-sectional analysis. PARTICIPANTS: Dementia-free community-dwellers aged 65. MEASURES: The PROOF participants underwent an extensive neuropsychological battery at baseline. Summary cognitive measures including memory, attention, and executive performance were created by converting the individual test results to Z scores and computing the average scores within each domain. Each of the three cognitive scores was individually compared between groups as a function of Met S. The cognitive scores and the covariates which were significant in univariate analyses were then included in logistic regression models. RESULTS: A significant association was observed between the presence of metabolic syndrome, poor memory, and executive function even after adjusting for confounding factors (memory: odds ratio: 1.77, p = 0.008; executive functions: odds ratio: 1.91, p = 0.002). CONCLUSIONS: Our study showed that in a sample of elderly community dwellers, Met S was associated with poor memory and executive performance. These results underline the importance of detecting and managing metabolic syndrome components to prevent cognitive impairment and dementia.
Assuntos
Função Executiva , Transtornos da Memória/epidemiologia , Síndrome Metabólica/epidemiologia , Idoso , HDL-Colesterol/sangue , Estudos Transversais , Feminino , Humanos , Hiperglicemia/complicações , Hiperglicemia/epidemiologia , Hiperglicemia/psicologia , Hipertensão/complicações , Hipertensão/epidemiologia , Hipertensão/psicologia , Hipertrigliceridemia/complicações , Hipertrigliceridemia/epidemiologia , Hipertrigliceridemia/psicologia , Masculino , Transtornos da Memória/etiologia , Síndrome Metabólica/complicações , Síndrome Metabólica/psicologia , Testes Neuropsicológicos , Fatores de RiscoRESUMO
OBJECTIVE: This study examined the dose-dependent effects of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) supplementation on heart rate variability (HRV) at rest and during standard laboratory stress tasks. We also investigated whether EPA + DHA supplementation was associated with changes in mood state. METHODS: This placebo-controlled, double-blind, randomized, three-period crossover trial (8-week treatment, 6-week washout) compared two doses of EPA + DHA supplementation (0.85 and 3.4 g/d) in 26 adults with elevated triglycerides. After each treatment period, HRV was assessed during an acute stress protocol that included a resting baseline, standard laboratory stress tasks (speech task and cold pressor), and recovery periods. In addition, mood state was assessed. RESULTS: Root mean square of successive differences in interbeat interval and total power increased 9.9% and 20.6%, respectively, after the high dose relative to placebo (Tukey p = .016 and .012, respectively). The low dose was not significantly different from the high dose or placebo dose. There was a trend for a treatment effect on high-frequency HRV (p = .058), with 21.0% greater power observed after the high dose compared with placebo (Tukey p = .052). Mood did not differ between treatments, and there was no association between mood state and HRV. CONCLUSIONS: In healthy adults with elevated triglycerides, supplementation of 3.4 g/d EPA + DHA resulted in greater HRV, whereas 0.85 g/d EPA + DHA had no effect. These results indicate that EPA + DHA supplementation may improve autonomic tone in adults at increased risk for cardiovascular disease within 8 weeks. TRIAL REGISTRATION: NCT00504309 (ClinicalTrials.gov).
Assuntos
Suplementos Nutricionais , Ácidos Graxos Ômega-3/farmacologia , Frequência Cardíaca/efeitos dos fármacos , Hipertrigliceridemia/tratamento farmacológico , Ansiedade/etiologia , Temperatura Baixa , Estudos Cross-Over , Depressão/etiologia , Ácidos Docosa-Hexaenoicos , Método Duplo-Cego , Combinação de Medicamentos , Ácido Eicosapentaenoico , Eletrocardiografia , Teste de Esforço , Ácidos Graxos Ômega-3/uso terapêutico , Humanos , Hipertrigliceridemia/fisiopatologia , Hipertrigliceridemia/psicologia , Descanso , Fala/fisiologia , Estresse Fisiológico , Estresse Psicológico/fisiopatologia , Estresse Psicológico/psicologiaRESUMO
OBJECTIVE: Previous research indicates that patients with severe symptoms of depression or anxiety are prone toward the development of dyslipidemia and abdominal obesity. We sought to study these associations longitudinally. METHODS: Among 2126 Netherlands Study of Depression and Anxiety participants, we studied whether severity of depressive (Inventory of Depressive Symptoms) or anxiety (Beck Anxiety Inventory) symptoms at baseline was associated with changes in lipids (i.e., total, high-density lipoprotein [HDL] or low-density lipoprotein cholesterol, and triglycerides) or waist circumference during a 2-year follow-up period. We also examined whether changes in severity of symptoms were associated with changes in lipid or waist circumference levels over these 2 years. Multivariate linear regression analyses were adjusted for age, sex, education, and tobacco consumption. RESULTS: Baseline symptoms of depression or anxiety predicted a decrease in HDL cholesterol (adjusted ß = -.062 [p = .003] and ß = -.050 [p = .02], respectively) and an increase in waist circumference (adjusted ß = .060 [p = .01] and ß = .053 [p = .02], respectively) for 2 years. Reduction of symptoms of depression or anxiety over time did not coincide with an amelioration of lipid or waist circumference values. CONCLUSIONS: People with initially severe symptoms of depression or anxiety showed a subsequent decrease in HDL cholesterol levels and an increase in abdominal obesity over time, independent of a potential reduction in symptom severity in this period. Therefore, such people are at elongated and increasing risk for dyslipidemia and obesity, predisposing them to cardiovascular disease.
Assuntos
Ansiedade/psicologia , Depressão/psicologia , Hipercolesterolemia/psicologia , Hipertrigliceridemia/psicologia , Obesidade Abdominal/psicologia , Adolescente , Adulto , Idoso , Estudos de Casos e Controles , HDL-Colesterol/sangue , LDL-Colesterol/sangue , Estudos de Coortes , Feminino , Humanos , Hipercolesterolemia/sangue , Hipertrigliceridemia/sangue , Estudos Longitudinais , Masculino , Pessoa de Meia-Idade , Países Baixos , Fatores de Risco , Índice de Gravidade de Doença , Triglicerídeos/sangue , Circunferência da Cintura , Adulto JovemRESUMO
OBJECTIVE: The aim of this study was to determine whether elevated depressive symptoms are associated with metabolic syndrome and its components in the Japanese population. METHODS: Out of 1,386 male workers who underwent measurements of variables of metabolic syndrome components in their health checkup, 1,186 subjects (44.5 ± 9.6 years) completed the Zung self-rating depression scale (ZSDS) (response rate 85.6%). In this study, metabolic syndrome was defined according to the joint scientific statement proposed by 6 major organizations, including the International Diabetes Federation. RESULTS: The overall frequency of elevated depressive symptoms (ZSDS scores ≥40) was 42.1% (n=499). The incidence of metabolic syndrome was significantly higher in subjects with elevated depressive symptoms than in those without (13.2% vs. 8.9%, p<0.05). Of all the metabolic syndrome components, mean triglyceride levels were significantly higher in subjects with elevated depressive symptoms than in those without [124.7 (95% confidence interval (CI): 117.8-131.7) mg/dL vs. 111.5 (95% CI: 107.2-115.9) mg/dL, p<0.05]. Consequently, hypertriglyceridemia (28.9% vs. 21.0%, p<0.01) was the main component correlated with the between-group difference of metabolic syndrome incidence. In the logistic regression analysis after adjustment for potential confounders, the odds ratio of the total ZSDS scores for the diagnosis of hypertriglyceridemia was 1.52 (95% CI: 1.13-2.04; p<0.01), and the major depressive symptom was psychomotor agitation (odds ratio: 1.47; 95% CI: 1.10-1.94; p<0.01). CONCLUSION: This study showed that elevated depressive symptoms were associated with hypertriglyceridemia in Japanese male workers, which affected the clinical diagnosis of metabolic syndrome.
Assuntos
Povo Asiático/etnologia , Depressão/etnologia , Hipertrigliceridemia/etnologia , Síndrome Metabólica/etnologia , Saúde Ocupacional/etnologia , Adulto , Idoso , Povo Asiático/psicologia , Depressão/epidemiologia , Depressão/psicologia , Humanos , Hipertrigliceridemia/epidemiologia , Hipertrigliceridemia/psicologia , Incidência , Masculino , Síndrome Metabólica/epidemiologia , Síndrome Metabólica/psicologia , Pessoa de Meia-Idade , Adulto JovemRESUMO
AIM: Metabolic syndrome (MetS) is highly prevalent in patients with bipolar disorder (BD). Little research has evaluated the risk profile of MetS and cardiovascular disease in different gender and age groups in these patients. Our aim is to evaluate the prevalence of MetS in Italian patients with BD stratified by gender and age, and to determine the correlates of MetS. METHODS: Subjects with BD were included and stratified by sex and age according to the following age groups: <30; 30-39; 40-49; 50-59; ≥ 60 years. Socio-demographic and clinical characteristics, lifestyle information, and comorbidity for cardiovascular diseases and diabetes were collected. MetS was diagnosed according to National Cholesterol Education Program Adult Treatment Panel III modified criteria. RESULTS: MetS was evaluated in 200 patients, with a prevalence of 26.5%. Men had higher rates of hypertension and hypertriglyceridemia, women had more abdominal obesity. Women had a peak of prevalence in the ≥ 60 years group, while men displayed high rates even in the young age groups. In young patients, MetS was associated with Cluster B personality disorders and less physical exercise. CONCLUSION: Our paper highlights the importance of evaluating MetS even in young patients with bipolar disorder, especially males. The strong association with lack of physical exercise suggests that the implementation of healthy behaviors might be relevant in order to prevent MetS and future adverse cardiovascular outcomes.
Assuntos
Transtorno Bipolar/complicações , Síndrome Metabólica/psicologia , Adulto , Fatores Etários , Idoso , Doenças Cardiovasculares/complicações , Doenças Cardiovasculares/psicologia , Diabetes Mellitus/psicologia , Feminino , Humanos , Hipertensão/complicações , Hipertensão/psicologia , Hipertrigliceridemia/complicações , Hipertrigliceridemia/psicologia , Itália/epidemiologia , Estilo de Vida , Masculino , Síndrome Metabólica/complicações , Síndrome Metabólica/epidemiologia , Pessoa de Meia-Idade , Obesidade/complicações , Obesidade/psicologia , Prevalência , Fatores de Risco , Fatores Sexuais , Fatores SocioeconômicosRESUMO
OBJECTIVE: Prevalence of cardiovascular disease is high in schizophrenia. Our aim is to estimate the prevalence of cardiovascular risk factors (CVRF) among schizophrenia patients. METHOD: National cross-sectional study in patients diagnosed with schizophrenia under treatment with second generation antipsychotics and admitted to short-stay hospitalisation units. RESULTS: A sample of 733 consecutively admitted patients was enrolled; the most prevalent CVRFs were smoking 71% (95% CI: 67-74%) and hypercholesterolemia 66% (61-70%) followed by hypertriglyceridemia 26% (26-32%), hypertension 18% (15-21%) and diabetes 5% (4-7%). Metabolic syndrome showed 19% (95% CI: 16-23%) prevalence or, according to updated definitions (Clin Cornerstone 7 [2005] 36-45), 24% (95% CI: 20-28%). The rate of patients within the high-risk range of a 10-year fatal cardiovascular event was 6.5%. CVRFs under routine management were diabetes (60%), hypertension (28%) and, to a lesser extent, dyslipemia (14%). Treatment for CVRFs was associated to gender, men for hypertension OR = 25.34, p < 0.03 and women for diabetes OR = 0.02, p < 0.03. CONCLUSION: We found that CVRFs in schizophrenia were prevalent and under-diagnosed, and thus with insufficient therapeutic management.
Assuntos
Conscientização , Doenças Cardiovasculares/epidemiologia , Esquizofrenia/epidemiologia , Psicologia do Esquizofrênico , Adulto , Antipsicóticos/efeitos adversos , Antipsicóticos/uso terapêutico , Doenças Cardiovasculares/diagnóstico , Doenças Cardiovasculares/etiologia , Doenças Cardiovasculares/psicologia , Comorbidade , Estudos Transversais , Diabetes Mellitus Tipo 2/diagnóstico , Diabetes Mellitus Tipo 2/epidemiologia , Diabetes Mellitus Tipo 2/psicologia , Feminino , Comportamentos Relacionados com a Saúde , Hospitalização , Humanos , Hipercolesterolemia/diagnóstico , Hipercolesterolemia/epidemiologia , Hipercolesterolemia/psicologia , Hipertensão/diagnóstico , Hipertensão/epidemiologia , Hipertensão/psicologia , Hipertrigliceridemia/diagnóstico , Hipertrigliceridemia/epidemiologia , Hipertrigliceridemia/psicologia , Masculino , Pessoa de Meia-Idade , Obesidade/diagnóstico , Obesidade/epidemiologia , Obesidade/psicologia , Risco , Esquizofrenia/tratamento farmacológico , Comportamento Sedentário , Fumar/efeitos adversos , Fumar/epidemiologia , Fumar/psicologia , EspanhaRESUMO
BACKGROUND: Both ethnicity and lifestyle may contribute to these abnormalities. High prevalences of obesity and metabolic disturbances in patients with bipolar disorder (BD) have been reported in western countries. However, reports about the prevalences in Asian countries remain scant. METHOD: The cross-sectional study included 117 patients diagnosed as BD and treated with lithium (Li), valproate (VPA), or both at a university psychiatric outpatient clinic. Their body mass index and plasma levels of glucose and lipid were measured. The prevalence of metabolic syndrome was determined based on the IDF 2005 criteria. RESULTS: 13.7%, 36.8%, 53.0%, 18.6%, and 61.0% of the patients met the criteria for hyperglycemia, hypertriglyceridemia, low high-density lipoprotein cholesterol (HDL-C), hypertension and large waist circumference, respectively. 33.9% of the patients met the IDF 2005 criterion for metabolic syndrome. The prevalence of metabolic abnormalities was significantly higher in patients who have been cotreated with second-generation antipsychotics (SGAs). CONCLUSION: This study provides evidence of high prevalence of metabolic syndrome in BD patients in Taiwan. Such metabolic disturbances can increase morbidity and mortality. Further studies that focus on the underlying mechanisms and effective intervention strategies are warranted.
Assuntos
Transtorno Bipolar/epidemiologia , Síndrome Metabólica/epidemiologia , Adulto , Análise de Variância , Antimaníacos/uso terapêutico , Antipsicóticos/uso terapêutico , Transtorno Bipolar/sangue , Transtorno Bipolar/tratamento farmacológico , Glicemia/metabolismo , HDL-Colesterol/sangue , Feminino , Humanos , Hipercolesterolemia/sangue , Hipercolesterolemia/epidemiologia , Hipercolesterolemia/psicologia , Hiperglicemia/sangue , Hiperglicemia/epidemiologia , Hiperglicemia/psicologia , Hipertrigliceridemia/sangue , Hipertrigliceridemia/epidemiologia , Hipertrigliceridemia/psicologia , Lipídeos/sangue , Compostos de Lítio/uso terapêutico , Masculino , Síndrome Metabólica/sangue , Síndrome Metabólica/psicologia , Obesidade/sangue , Obesidade/epidemiologia , Prevalência , Taiwan/epidemiologia , Ácido Valproico/uso terapêuticoRESUMO
Increased levels of cholesterol have been reported in patients with bulimia nervosa (BN), but all but one of the published studies were performed on non-fasting subjects, which limits the interpretation of this finding. Moreover, the relationships between serum lipids and comorbid psychiatric disorders or bulimic psychopathology have scarcely been investigated. We measured serum levels of total cholesterol, triglycerides, glucose, 17beta-estradiol and thyroid hormones in 75 bulimic women and 64 age-matched healthy females after an overnight fast. Compared with healthy women, bulimic patients exhibited significantly enhanced serum levels of cholesterol and triglycerides, but similar values of glucose, 17beta-estradiol, FT3 and FT4. No significant differences emerged in these variables between patients with or without comorbid depression, borderline personality disorder or lifetime anorexia nervosa. Circulating cholesterol was positively correlated to the patients' drive for thinness, ineffectiveness, enteroceptive awareness and impulse regulation sub-item scores of the Eating Disorder Inventory-2. These findings confirm that BN is associated with increased levels of serum lipids. This alteration may be involved in the pathophysiology of certain psychopathological characteristics of BN and cannot be explained by the co-occurrence of other psychiatric disorders.
Assuntos
Bulimia/epidemiologia , Estradiol/sangue , Hipercolesterolemia/epidemiologia , Hipertrigliceridemia/epidemiologia , Transtornos Mentais/epidemiologia , Tiroxina/sangue , Tri-Iodotironina/sangue , Adulto , Anorexia Nervosa/sangue , Anorexia Nervosa/epidemiologia , Anorexia Nervosa/psicologia , Glicemia/metabolismo , Transtorno da Personalidade Borderline/sangue , Transtorno da Personalidade Borderline/epidemiologia , Transtorno da Personalidade Borderline/psicologia , Bulimia/sangue , Bulimia/psicologia , Colesterol/sangue , Comorbidade , Transtorno Depressivo/sangue , Transtorno Depressivo/epidemiologia , Transtorno Depressivo/psicologia , Jejum/sangue , Feminino , Humanos , Hipercolesterolemia/sangue , Hipercolesterolemia/psicologia , Hipertrigliceridemia/sangue , Hipertrigliceridemia/psicologia , Transtornos Mentais/sangue , Transtornos Mentais/psicologia , Inventário de Personalidade/estatística & dados numéricos , Psicometria/estatística & dados numéricos , Psicopatologia , Valores de Referência , Estatística como Assunto , Triglicerídeos/sangueRESUMO
To assess relationships of total plasma cholesterol (TC) and triglyceride (TG) values to suicide, suicide ideation, and hospitalization for psychiatric disease, we studied 220 children, ages 5 to 18 y, hospitalized with affective, adjustment, disruptive, anxiety, schizophrenic, other, and organic psychiatric disorders. The 135 male and 85 female patients had higher TG values (p = 0.0001 and 0.0003, respectively) and higher Quetelet Indices (p = 0.0001 and 0.003, respectively) than the 732 male and 316 female schoolchild controls; male patients had higher TC values than male controls (p = 0.014). Substance abuse in patients was an independent inverse determinant of TC value (p = 0.05); TG value correlated positively with alcohol use (p < or = 0.1) and substance abuse (p < 0.05). After covariance adjustment for age, race, sex, and Quetelet, children having adjustment disorders with depression had much lower covariance-adjusted TC value than control schoolchildren (3.91 versus 4.29 mmol/L, p = 0.003), whereas those with disruptive behavior with oppositional defiant disorder had much higher adjusted TC value (5.09 mmol/L, p = 0.0001). After covariance adjusting for age, race, sex, Quetelet, cigarette smoking, alcohol use, and substance abuse, children having adjustment disorders with concomitant depression had the highest group suicide tendencies (attempts and ideation) and the lowest covariance-adjusted TC value (4.03 mmol/L). Conversely, children having disruptive behavior with attention deficit hyperactivity disorder or disruptive behavior with oppoistional defiant disorder had 50% lower suicide index than those with adjustment disorders with concomitant depression and higher adjusted TC levels (4.45 and 5.12 mmol/L, p = 0.0003).(ABSTRACT TRUNCATED AT 250 WORDS)
Assuntos
Colesterol/sangue , Hipertrigliceridemia/psicologia , Transtornos Mentais/sangue , Suicídio , Transtornos de Adaptação/sangue , Adolescente , Alcoolismo/sangue , Análise de Variância , Criança , Pré-Escolar , Colesterol/deficiência , Depressão/sangue , Feminino , Hospitalização , Humanos , Masculino , Transtornos Relacionados ao Uso de Substâncias/sangue , Tentativa de SuicídioRESUMO
In 14 men and nine women referred because of severe primary hypertriglyceridemia, our specific aim in a 54-week single-blind treatment (Rx) period was to determine whether triglyceride (TG) lowering with a Type V diet and Lopid would lead to improvement in symptoms of depression, improvement in an index of life stressors, change in locus of control index, and improved cognition, as serially tested by Beck (BDI), Hassles (HAS) and HAS intensity indices, Locus of Control index, and the Folstein Mini-Mental status exam. On Rx, median TG fell 47%, total cholesterol (TC) fell 15%, and HDLC rose 19% (all p < or = 0.001). BDI fell at all nine Rx visits (p < or = 0.001), a major reduction in a test of depressive symptoms. The HAS score also fell at all nine visits (p < or = 0.05 - < or = 0.001). Comparing pre-Rx baseline BDI vs BDI at 30 and 54 weeks on Rx, there was a major shift towards absence or amelioration of depressive symptoms (chi 2= 5.9, p = 0.016). On Rx, the greater the percent reduction in TG, the greater the percent fall in BDI (r = 0.47, p < or = 0.05); the greater the percent reduction in TC, the greater the percent fall in HAS (r = 0.41, p < or = 0.05). Improvement in the BDI and HAS accompanied treatment of severe hypertriglyceridemia, possibly by virtue of improved cerebral perfusion and oxygenation. There may be a reversible causal relationship between high TG and symptoms of depression.